Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Invivyd

< Previous 1 2 Next >
Invivyd Announces CEO Transition
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd to Participate in Upcoming Investor Conferences
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd to Participate in Upcoming Investor Conferences
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Appoints William Duke as Chief Financial Officer
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Announces Appointment of Sara Cotter to Board Of Directors
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd to Participate at the Jefferies Healthcare Conference
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Reports First Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd to Participate at H.C. Wainwright’s BioConnect Investor Conference
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy Price as Chief Technology and Manufacturing Officer
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Doses First Participants in Phase 1 Trial of VYD222, a Novel Monoclonal Antibody Candidate for COVID-19
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Reports Full Year 2022 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd Publishes Model for Evaluating Biomarker Correlates of Protection for Monoclonal Antibodies Against Symptomatic COVID-19
From Invivyd
Via GlobeNewswire
Tickers IVVD
Invivyd to Host Conference Call Discussing Full Year 2022 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Tickers IVVD
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.